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The alarming global rise of antimicrobial resistance combined with the lack of new antimicrobial agents has led
to a renewed interest in optimization of our current antibiotics. Continuous infusion (CI) of time-dependent
antibiotics has certain theoretical advantages toward efficacy based on pharmacokinetic/pharmacodynamic
principles. We reviewed the available clinical studies concerning continuous infusion of beta-lactam antibiotics
and vancomycin in critically ill patients. We conclude that CI of beta-lactam antibiotics is not necessarily more
advantageous for all patients. Continuous infusion is only likely to have clinical benefits in subpopulations of
patients where intermittent infusion is unable to achieve an adequate time above the minimal inhibitory
concentration (T>MIC). For example, in patients with infections caused by organisms with elevated MICs,
patients with altered pharmacokinetics (such as the critically ill) and possibly also immunocompromised patients.
For vancomycin CI can be chosen, not always for better clinical efficacy, but because it is practical, cheaper,
associated with less AUC24h (area under the curve >24 h)-variability, and easier to monitor.
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Pharmacokinetic/pharmacodynamicBackground
Antimicrobial resistance is emerging worldwide [1]. In
addition there is a dramatic lack of new antimicrobial
agents being explored in phase 2 or 3 clinical trials, es-
pecially for Gram-negative organisms, and development
of an antimicrobial with a genuinely novel mechanism of
action is estimated to take years [2].
These evolutions have spurred interest in maximizing
the effectiveness of our current antimicrobial armament-
arium to retain its activity for the years to come. One of
the ways to achieve this is through optimization of anti-
biotic dosing regimens based on pharmacokinetic/phar-
macodynamic (PK/PD) principles. Animal studies and
PK/PD studies suggest that efficacy of beta-lactam anti-
biotics is better when administered as continuous infu-
sion (CI) or prolonged infusion than when administered
as intermittent infusion (II), yet this remains to be* Correspondence: Bruno.van.herendael@uza.be
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reproduction in any medium, provided the origproven in clinical outcome studies. CI of vancomycin
also is increasingly popular, albeit more for practical rea-
sons and aiming to limit toxicity rather than for reasons
related to PK/PD and expected clinical efficacy. In this
paper, we therefore focus on the clinical evidence for CI
of both the beta-lactam antibiotics and vancomycin in
critically ill patients.Review
β-lactam antibiotics
Beta-lactam antibiotics are “time-dependent antibiotics”.
Their maximal killing rate is achieved at concentrations
that are only about four times the minimal inhibitory
concentration (MIC), which is a relatively low concen-
tration if considering the actual serum levels that are
achieved by intermittent administration (typical Cmax
will reach values> 80 mg/L), and the current clinical
breakpoints of beta-lactams (i.e., the highest MIC that
an antibiotic may show against a given organism while
keeping a high likelihood of clinical success) that rarelyThis is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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the MIC do not lead to more bacterial killing [3-5]. For
beta-lactam antibiotics, therefore, not the peak concen-
tration (nor the area under the curve as such) correlates
best with efficacy, but rather the fraction of the time
during which the serum concentration of the antibiotic
exceeds the MIC between two successive administrations
(T>MIC) [3,6]. For most non-life-threatening infections
in nonimmunocompromised patients, a T>MIC of 40–
50% is sufficient for successful clinical outcome. Animal
studies with Streptococcus pneumoniae infected nonneu-
tropenic mice showed that survival reached a plateau
(with excellent survival) if serum levels exceeded the
MIC for no longer than 40–50% of the dosing interval
(reviewed in [7]). A recent human study, however, sug-
gests that for critically ill patients clinical outcome might
be better if T>MIC approximates the full 100% [8]. Al-
though T>MIC is the most important parameter it also
is important to achieve a steady state concentration
(Css) of at least 2.5 times the MIC and preferably 4
times the MIC. Mouton and Hollander [9] showed that
a Css equal to or slightly above the MIC during continu-
ous infusion can lead to selection of resistant subpopula-
tions in vitro. In a study from Alou and coworkers [10],
the authors advise a Css/MIC ratio of at least 2.5, be-
cause they found bacterial regrowth when the Css/MIC
ratio was 1.26, but not when it was 2.5.
Several PK/PD studies with different beta-lactam anti-
biotics have shown that their administration by CI sig-
nificantly increases the likelihood of maintaining serum










Ceftazidime [25]6 g/24 h 75 ≤1 75
Ceftazidime [26]4.5 g/24 h 47 ≤1 47
Ceftazidime [27]3 g/24 h 30 ≤1 30
Ceftazidime [28]60 mg/kg/d 19 ≤1 19
Ceftazidime [29]4 g/24 h 40 ≤1 40
Ceftazidime [11]6 g/24 h 63 ≤1 63
Cefepime [30]4 g/24 h 41 ≤1 41
Cefepime [31]4 g/24 h 13.5 ≤1 13.5
Piperacillin [32]13.5 g/24 h 35 ≤8 4.37
Piperacillin [33]12 g/24 h 18 ≤8 2.25
Meropenem [15]3 g/24 h 7 ≤2 3.5
EUCAST = European Committee on Antimicrobial Susceptibility Testing; CLSI = Clinic
MIC =minimal inhibitory concentration.when considering the highest clinical susceptibility
breakpoints [10-18]. This is well illustrated in study by
Alou and coworkers [10] who used a pharmacokinetic
computerized model to simulate concentrations of cefta-
zidime in human serum after administration of 6 g/day
using either CI or II. Using isolates with MICs of 8, 16,
and 32 mg/L, the authors found a T>MIC of 99.8%,
69%, and 47.6%, respectively, for the bolus regimen and
100% for all strains with CI. Therefore, a first population
at risk to consider for CI is patients with infections
caused by pathogens with MICs close to the susceptibil-
ity breakpoint. A second at-risk population are critically
ill patients where altered physiology with increased vol-
ume of distribution (Vd) and increased drug clearance
can lead to lower initial as well as faster decreasing
serum concentrations than expected for typical drug
dosages [19,20]. This adds a direct pharmacokinetic ar-
gument to the well-accepted necessity to ensure a longer
T>MIC in critically ill patients compared with other
patients for pharmacodynamic reasons [8]. A third
population at risk might be neutropenic patients. A
series of animal studies [21-24] comparing clinical out-
come after CI versus II in rats with pulmonary infection
shows a clear benefit in neutropenic rats in favor of CI.
The daily dose needed to protect 50% of the rats from
mortality was 15 times lower with CI. This effect disap-
peared in nonneutropenic animals.
Patients in the ICU are at risk for infections with
higher MICs. For these infections, it can be quite diffi-
cult to achieve acceptable PK/PD targets with classical
intermittent dosing regimens. Even when using CI, theontinuous infusion of different antimicrobials in critically
Pseudomonas aeruginosa







≤4 18.75 ≤8 9.37
≤4 11.75 ≤8 5.87
≤4 7.5 ≤8 3.75
≤4 4.75 ≤8 2.37
≤4 10 ≤8 5
≤4 15.75 ≤8 7.87
≤8 5.13 ≤8 5.13
≤8 1.68 ≤8 1.68
≤16 2.18 ≤16 2.18
≤16 1.125 ≤16 1.125
≤1 7 ≤2 3.5
al and Laboratory Standards Institute; Css = steady state concentration;
Table 2 Characteristics of studies comparing outcome for continuous versus intermittent administration of piperacillin
Study Drug Patient population Dosage Study type Outcome measure Outcome Remarks
Grant 2002
[49]
Piperacillin-tazobactam Hospitalized patients 12 g/d CI (n= 47)























12 g/d CI (n= 130)










Piperacillin Septic, critically ill
patients
8 g/d CI (n = 20)

















ICU patients (n= 126) and
non-ICU patients (n= 68)
3 x 3.375 g/d in
extended infusions
of 4 h (n= 102) vs.
















Lower antimicrobial dose in extended infusion
group Significant outcome differences only in








VAP 16 g/d CI (n= 37) vs.









Significant outcome differences only in infections
caused by pathogens with high MICs
*Studies that included critically ill, ICU patients.
NS = nonsignificant; MIC =minimal inhibitory concentration; CI = continuous infusion; II = intermittent infusion; APACHE II = Acute Physiology and Chronic Health Evaluation; VAP= ventilator-associated pneumonia;
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bility breakpoint and critically ill patients with lower than
expected Css (because of increased Vd and increased drug
clearance) can lead to critically low Css/MIC ratios below
the advised ratio of 2.5 to 4. An overview of studies
[11,15,25-33] investigating PK-parameters of continuous in-
fusion of different antimicrobials in critically ill patients is
shown in Table 1. In most of these studies, the Css/MIC
ratio is well above 2.5. However, for cefepime (at a submaxi-
mal dosage of 4 g/d) [31] and piperacillin (at a submaximal
dosage of 12 g/d) [33], the ratio became problematically low
for pathogens with MICs close to the susceptibility break-
point with subsequent risk of therapeutic failure or emer-
gence of resistance. Yet, for any MIC, continuous infusion
has a higher likelihood of attaining PK/PD targets than II. So
when starting empirical therapy, CI is the safer choice. If
however after culture the pathogen proves to be resistant (or
even in the intermediate range) another antimicrobial should
be chosen. Obtaining a MIC for the causative pathogen in
case of severe infection will give even more information than
relying on “susceptible/intermediate/resistant” categories
only. The value of the MIC can be directly compared with
the breakpoints and can be used to guide therapy.
General clinical value of CI of β-lactam antibiotics
In 2009, a meta-analysis was published of all randomized
controlled trials (RCT) from 1950 through November 2007
comparing the clinical benefits of CI regimens of beta-
lactam antibiotics with II regimens [34]. The meta-analysis
included 14 RCTs with a total of 846 patients [16,17,25,35-
44]. No difference was found for mortality or clinical cure
between II or CI. Yet, all but one of the included studies
used a higher drug dose in the bolus group than in the CI
group, and the authors concluded that CI of a lower dosed
beta-lactam antibiotic might lead to the same clinical
results as II of the same higher dosed antibiotic. Apart from
the different daily dosages, another important limitation
was that most studies analyzed a heterogeneous population
with underrepresentation of the critically ill, a population
where CI is expected to be advantageous.
Penicillins
For penicillin G and flucloxacillin, most data come from
observational, noncontrolled studies often in home-
based care settings [45-47]. Both antibiotics proved to be
safe when given in CI and achieved an excellent clinical
cure rate in stable, noncritically ill patients. Only one
study included critically ill patients, but CI was only
started after clinical improvement was achieved with II
[47]. All previous studies had no comparator group of
patients with II. One retrospective study did compare
outcome between CI (n= 78) and II (n = 28) of oxacillin
for treatment of MSSA (methicillin susceptible Staphylo-
coccus aureus) endocarditis. They found similar results formortality (8% vs. 10%, p=0.7) and length of stay, but
microbiological cure at 30 days, defined as “no positive
cultures within 30 days of the end of treatment”, differed
significantly with odds ratio of 3.8 in favor of CI [48].
Five clinical trials have been published in regards to CI
of piperacillin-tazobactam (Table 2). Two of these found
no difference for clinical cure rates between CI and II of
piperacillin-tazobactam [42,49], although Grant et al.
[49] concluded that the costs in the CI group were sig-
nificantly lower than in the II group. These two studies
did not include critically ill patients. Others observed
that the severity of illness, measured by APACHE II
scores, decreased more rapidly in the CI group of septic
patients even though this group received a lower daily
dosage [16]. Two retrospective cohort studies described
higher rates of clinical cure in the CI arm, but only in
subpopulations with the most critically ill patients [50]
or with infections caused by more resistant organisms
[51]. The last three studies were performed with critic-
ally ill, intensive care unit (ICU) patients.Cephalosporins
Studies comparing clinical outcome between CI and II
of cephalosporins are listed in Table 3. Four showed
comparable clinical cure rates [17,28,38,41]. However,
most used a lower daily dose in the CI arm than in the
II arm [17,28,38]. In the studies by Hanes and Georges,
both CI and II regimens achieved T>MIC> 90%, which
explains the comparable outcomes [28,41].
Three studies showed a clinical advantage with continu-
ous infusion; however, mostly only in a subpopulation.
Roberts and coworkers [35] compared CI of ceftriaxone
versus II in 57 intensive care patients with sepsis and
found a significant advantage in favor of CI only in an a
priori-defined subgroup of patients (n= 50) who received
more than 4 days of antibiotic therapy, but not in the
intention-to-treat analysis that included all patients
(n= 57). This subgroup analysis was performed to exclude
patients who were either moribund (too ill) or did not
need antimicrobial treatment (not ill enough). A retro-
spective study by Lorente et al. showed a greater clinical
cure rate for CI versus II of ceftazidime (and tobramycin)
for the treatment of critically ill patients with ventilator-
associated pneumonia (VAP) [52]. Both arms received a
low total daily dose of 4 g/d (instead of the standard dos-
age of 6 g/d). This could have influenced results, because
with suboptimal dosages the chances to attain an accept-
able T>MIC are much higher with CI. Finally, an older
study [36] found that continuous cefamandole infusion
(with carbenicillin in II) achieved a greater effectiveness
than intermittent carbenicillin infusion (with carbenicillin
in II) in a subgroup of patients with persistent severe
neutropenia.
Table 3 Characteristics of studies comparing outcome for continuous versus intermittent administration of cephalosporins





6 x 5 g/d)
FUO in neutropenic
patients
12 g/d CI (n = 74) vs.
4 x 3 g/d II (n = 92)
RCT Clinical cure NS Significant difference in clinical cure (in favor of CI)





in critically ill trauma
patients
60 mg/kg/d CI (n = 17)
vs. 3 x 2 g/d II (n = 15)








T>MIC> 90% in both II and CI groupLower








3 g/d CI (n= 17) vs.












VAP 4 g/d CI (n= 56) vs.





Clinical cure CI> II(p< 0.001)
*Roberts 2007
[35]
Ceftriaxone Sepsis 2 g/d CI (n= 29) vs.







Significant difference in clinical cure only in an ‘a priori’
defined subgroup of patients who received at least 4
days of ceftriaxone therapy (to exclude patients that
were not ill enough or too ill)
Van Zanten
2007[17]
Cefotaxime COPD exacerbations 2 g/d CI (n= 47) vs.
3 x 1 g/d II (n = 46)








4 g/d CI (n= 26) vs.
2 x 2 g/d II (n = 24)
RCT Clinical cure NS
*Studies that included critically ill, ICU patients.
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A retrospective cohort study with 89 patients [53] com-
paring CI versus II of meropenem for the treatment of
VAP due to Gram-negative bacilli found a significantly
better clinical cure rate in the group with CI, especially
when used for Pseudomonas species and other patho-
gens with elevated MIC values. The authors used 6-h
infusions, although it is generally not advised to give
meropenem in infusions longer than 3–4 h for reasons
of stability. Sakka conducted a study in which 20 critic-
ally ill patients with pneumonia were randomized to re-
ceive either a normal dose (3 x 1 g/d) of imipenem-
cilastatin by II (n = 10) or a lower dose (2 g/d) by CI
(n = 10) [44]. Both regimens achieved excellent target at-
tainment with T>MIC 100% for all patients, which
explains the similar outcomes with one patient who died
in the CI group and two patients in the II group. Both
studies are listed in Table 4.
With regards to the threat of the emerging
carbapenemase-producing Enterobacteriaceae, it has been
suggested in a recent review that carbapenemase-producing
Klebsiella pneumoniae with a MIC up to 4 mg/L (higher
than the EUCAST (European Committee on Antimicrobial
Susceptibility Testing) susceptibility breakpoint of 2 mg/L
and the CLSI (Clinical and Laboratory Standards Institute)
susceptibility breakpoint of 1 mg/L can still be treated with
carbapenems if they are given in an extended infusion and
higher dosage regimen [54]. This could create a treatment
option in situations where alternatives are extremely limited.Temocillin
Only one study has been published concerning CI of the
niche antibiotic temocillin [13]. Temocillin remains
stable and therefore active in CI and is compatible with
aminoglycosides (but not with several other antibiotics).
Moreover, the standard dose of 4 g/d yields stable serum
concentrations >16 mg/L, the breakpoint of temocillin
for Enterobacteriaceae. Unfortunately, the study was not
powered to compare clinical outcome. A study using a
6-g/d dosage in the ICU with a measure of clinical out-







Meropenem VAP with gram
negative bacilli
4 g/d CI (n= 42)







2 g/d CI (n= 10)
vs. 3 x 1 g/d (n= 10)
RCT
*Studies that included critically ill, ICU patients.
VAP = ventilator-associated pneumonia; RCT = randomized, controlled trial.CI of beta-lactam antibiotics: Discussion
The available clinical evidence, also in critically ill patients,
does not show a conclusive and significant benefit in favor
of CI. This might be due to the fact that CI is only likely to
have clinical benefits in the subpopulation of patients for
whom II is unable to achieve an adequate T>MIC: for ex-
ample, in patients with infections caused by borderline sus-
ceptible organisms, patients with elevated drug clearance or
increased Vd (such as the critically ill), and possibly also im-
munocompromised patients. These populations are difficult
to include in homogenous cohorts, and the underlying
pathologies may obscure the final picture. However, it is fair
to say that in the small numbers of clinical studies that did
show an advantage in favor of CI, this effect was only
present or more pronounced in a subpopulation of the
most critically ill or patients with infections caused by
pathogens with elevated MICs. An important limitation of
most of the older studies is that they are primarily designed
to prove that a lower dose of an antibiotic given in CI can
be equally effective as a higher dose given in an intermittent
bolus regimen and consequently use lower dosages in the
CI arm. Finally, some studies use a second antibiotic, which
could be responsible for bias.
Future studies should ideally include a homogeneous
population and PK/PD analysis (including the MICs of the
responsible pathogens and therapeutic drug monitoring) to
know which patients attain PK/PD targets and how this is
linked with either infusion regimen and/or outcome. How-
ever, serum level determinations for beta-lactam antibiotics
are not routinely available, and therefore, PK/PD analysis
has only recently gained attention in the ICU world.
Apart from clinical efficacy, there are some other
advantages in favor of CI. Several studies show that the
costs associated with CI are lower than with II [49,55].
There also is some evidence that tissue penetration
might be better with CI. Roberts et al. found that con-
centration at the subcutaneous tissue was higher when
meropenem was administered by CI than when it was
administered by II in critically ill patients [15]. Another
study shows that the penetration of ceftazidime in
patients with severe abdominal infections was better






Clinical cure CI> II(p< 0.001)
Clinical cure NS Lower antimicrobial dose in
CI groupT>MIC=100 % in
both II and CI group
Table 5 List of drugs that are incompatible with different time-dependent antibiotics when given trough the same
intravenous line (Y-site incompatibilities)
Time-dependent antibiotic Incompatible drugs (should not be given trough the same intravenous line)
Flucloxacillin [64] Clarithromycin, lorazepam, midazolam, vancomycin
Ceftazidime [61,64] Acetylcysteine, nicardipine, midazolam, propofol, and vancomycin
Cefepime [62,64] Erythromycin, propofol, midazolam, phenytoin, piritramide, theophylline, nicardipine, N-acetylcysteine,
vancomycin, and a concentrated solution of dobutamine
Piperacillin-tazobactam [64] Acyclovir, amiodarone, amphotericin B cholesteryl sulfate complex, azithromycin, dobutamine,
ganciclovir, haloperidol, vancomycin
Meropenem [64] Acyclovir, amphotericin B, diazepam, ondansetron, doxycycline
Imipenem [64] Allopurinol, amiodarone, amphotericin B cholesteryl sulfate complex, azithromycin, fluconazole,
lorazepam, midazolam,
Temocillin [13] Other beta-lactam antibiotics, vancomycin, ciprofloxacin, clindamycin, propofol, midazolam,
nicardipine, ranitidine, vitamin K
Vancomycin [unpublished data by Ampe E,
article in preparation]
Flucloxacillin, temocillin, piperacillin-tazobactam, cephalosporins, imipenem, moxifloxacin, propofol,
valproate, phenytoin, theophylline, furosemide, methylprednisolone
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The antibiotic dosage should be adjusted to achieve a
serum steady state target concentration approximately
four times the MIC of the pathogen, and a loading dose
should be administered to reach a steady state more rap-
idly. Several formulas have been proposed for calculation
of loading dose and total daily dose [56]:
Total daily dosage (mg) = 24 (h) x total body clearance
(L/h) x target Css (mg/L)
Loading dose (mg) = target peak concentration (mg/L)
x volume of distribution (l)
AUC24h =Total daily dosage /[{(creatinine clearance x
0.79) + 15.4} x 0.06]
However, the value of these formulas is limited in a crit-
ically ill population; they presume knowledge of volume of
distribution (Vd) and total body clearance (TBC), which is
problematic in an ICU population. In critically ill patients,
the Vd is elevated and difficult to predict. Second, the TBC
of beta-lactams is not always readily predictable from the
value of creatinine clearance (even for antibiotics such as
ceftazidime that are essentially eliminated by the kidney),
and moreover, in the critically ill there is no readily avail-
able method to measure accurately the glomerular filtra-
tion rate (GFR) [57]. The risk of underdosing is certainly
higher than the risk of possible toxicity in ICU patients.
Because no clinical or biological variable can predict beta-
lactam concentrations in critically ill patients, we agree
with other authors that therapeutic drug monitoring of
beta-lactam antibiotics might be necessary in this popula-
tion [58]. Because beta-lactams are rather safe drugs, a
practical approach commonly used is to start with a load-
ing dose equal to the first dose normally administered
when using II, followed immediately by CI using the same
total daily dose as in II (note that in doing so, one creates
essentially a single serum peak equivalent to what is
obtained repeatedly with II).Not all beta-lactam antibiotics are stable enough for a
24-h infusion. Piperacillin [59], temocillin [13], and
aztreonam [59,60] are stable at room temperature for at
least 24 h. Ceftazidime and cefepime are stable for 24 h
at 25°C, but only for 8 h and 13 h, respectively, at 37°C
[59,61,62]. This means they can be used as 24-h infusion
without problems if temperature does not exceed 25°C,
but home administration with portable pumps next to
the body or hospital administration in regions or periods
of warm climate can pose problems because of higher
temperatures. Meropenem, doripenem, and especially
imipenem are less stable and should only be given as
extended 3- or 4-h infusions [63]. Amoxicillin is stable
at room temperature for 8 h [64] and penicillin for 12 h
[65]. Certain physical or chemical incompatibilities with
other drugs for infusion through the same intravenous
line (Y-site infusion) have been described. Most notable
is the incompatibility with vancomycin for most beta-
lactam antibiotics. An overview of all incompatibilities is
listed in Table 5. If concomitant administration of Y-site
incompatible drugs is necessary, they should be admini-
strated trough separate intravenous lines.
Vancomycin
Vancomycin has a different PK/PD pattern. Like beta-
lactam antibiotics, vancomycin also exhibits slow and
time-dependent killing during in vitro experiments.
However, unlike the beta-lactams, vancomycin has mod-
erately long postantibiotic effects (i.e., withdrawal of the
antibiotic is not immediately followed by bacterial re-
growth). Therefore, it becomes less important for serum
concentrations to remain above the MIC all the time [66].
Moreover, vancomycin has a much longer serum half-life
than most β-lactams, which makes the drug remain above
the MIC for most of the administration interval (especially
if considering the recently revised clinical breakpoints of
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ceptible and to >2 for resistant to avoid recommending
the use of vancomycin against organisms with higher
MICs that would only poorly respond to the antibiotic).
Careful animal studies where T>MIC could be unam-
biguously separated from other PK parameters (which is
difficult to obtain in human studies) showed that it is ac-
tually AUC24h/MIC (area under the curve over 24 h) that
best predicts clinical efficacy [67-70].
AUC24h is a parameter that is more difficult to grasp
than the T>MIC, but it is proportional to the total daily
dosage (TDD) and inversely proportional to the creatinine
clearance (CrCl) [69]. Consequently the AUC24h will in-
crease if a greater TDD is given, irrespective of continuous
or intermittent dosing. An AUC24h/MIC> 350 was asso-
ciated with clinical success and an AUC24h/MIC> 400
with faster bacterial eradication in patients receiving
vancomycin for Staphylococcus aureus pneumonia [69]. In
continuous infusion, the AUC24h is simply the product of
the actual serum concentration x24. Based on the above
observations concerning the required AUC24h/MIC ratio,
it means that a stable serum level of 14 to 18 times the
MIC must be maintained to achieve optimal efficacy.
Clinical value of CI of vancomycin
A prospective, randomized trial in 114 patients treated
for severe staphylococcal infections compared outcome,
safety, and cost of CI versus II infusion of vancomycin
[71]. Outcome and safety were similar between the two
groups, but with CI target concentrations were achieved
more quickly, there was less variability of AUC24h values,
and costs were lower. Vuagnat et al. conducted a non-
randomized, prospective trial with 44 patients who
required high-dose vancomycin for treatment of osteo-
myelitis [72]. Twenty-one patients received vancomycin
through II and 23 through CI. Outcome was equal with
both regimens but with CI target concentrations were
achieved more quickly, there was less variability of
serum concentrations and also less adverse reactions
were seen, including renal injury. A small, retrospective
study in critically ill patients found that CI was asso-
ciated with a faster decrease in leukocyte count and clin-
ical severity score but not with differences in morbidity
or mortality [73]. One matched cohort study reported
lower mortality rates for critically ill patients with VAP
receiving vancomycin in CI (25% vs. 55%). Multiple re-
gression analysis of the data confirmed that CI was asso-
ciated with improved survival. Unfortunately, this study
was not designed to compare CI and II and thus PK/PD
data are lacking [74].
Two major clinical studies compared nephrotoxicity
between different vancomycin dosing regimens [75,76].
In a study in which 167 outpatients received vancomycin
through CI (n = 112) or through II (n = 55), Ingram et al.found that CI is associated with a slower onset, but not
a lower prevalence (15.6%), of nephrotoxicity [75]. A
nonsignificant tendency toward less nephrotoxicity in
favor of CI was seen in 149 patients after cardiac surgery
[76].
Byl et al. compared the pleural and serum vancomycin
concentrations in 16 patients receiving continuous or
intermittent vancomycin infusion and found no differ-
ence for AUC24h between the two groups, but antibiotic
levels were more sustained with CI [77].CI of vancomycin: Discussion
The actual data show no difference in clinical outcome
between continuous and intermittent dosing regimens.
But for vancomycin, in contrast to the beta-lactams, we
expected this; as we have seen, AUC24h/MIC is the PK/
PD parameter best predictive of clinical efficacy and is
dependent only on TDD and renal function.
If not for attaining better clinical efficacy, what other
reasons are there for choosing a CI regimen? The study
from Wysocki et al. suggests that CI is cheaper, logistically
more convenient, achieves target concentrations faster,
and results in less variability of the AUC24 compared with
II [71]. On a busy nursing ward, it may be easier to obtain
a reliable Css than a reliable through concentration, be-
cause the first can be obtained at almost any time during
the administration period.
The subject of nephrotoxicity is of growing importance,
because there is a tendency toward higher, and potentially
more nephrotoxic, dosing of vancomycin to attain the
advocated PK/PD-target of AUC24h> 400/MIC. As men-
tioned, two studies have suggested that CI might be asso-
ciated with a slower onset of nephrotoxicity [75,76].
Wysocki et al. [71] also states that continuous infusion
with a target Css of 20–25 mg/L is safe, and a recent meta-
analysis of available data found that CI is associated with a
significantly lower risk of nephrotoxicity compared with II
[78]. However, a recent, retrospective, cohort study of 129
patients who received vancomycin in CI with a target Css
of 15–25 μg/mL contradicts the belief that CI is less
nephrotoxic than II and finds a high proportion of patients
with acute kidney injury (29.5%) [79]. This study had no
comparator group of patients with II. Data on toxicity for
continuous versus intermittent infusion of vancomycin are
conflicting, and no conclusive recommendations can be
made [80].
Because there is no evidence for outcome benefit and
because data on renal toxicity are conflicting, recent
guidelines from the Infectious Diseases Society of Amer-
ica (IDSA) concerning the treatment of methicillin-
resistant Staphylococcus aureus (MRSA) do not support
the generalized use of a continuous infusion for vanco-
mycin in these circumstances [81].
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Recent consensus recommendations suggest a vancomycin
starting dose of 15–20 mg/kg every 8–12 h for II with a
loading dose of 25–30 mg/kg [70]. These recommendations
for loading dose and TDD can be applied to CI or the
dosages can be individualized according to PK/PD targets.
The formulas proposed for calculation of individualized
dosages are the same as those mentioned for beta-lactam
antibiotics. These formulas also suffer from the same short-
comings, as mentioned, for beta-lactam antibiotics and are
not readily applicable in critically ill patients. However, they
can be used to demonstrate the thin line between thera-
peutic and toxic vancomycin dosages. For example, attain-
ing an AUC24h/MIC of 400 for a patient with a CrCl of
100 ml/min and a pathogen with a MIC of 1 mg/L would
require a total daily dose of 2,300 mg of vancomycin. For a
MIC of 2 mg/L (the EUCAST susceptibility breakpoint for
vancomycin against MRSA), this would mean a total daily
dose of 4,500 mg, which approximates a Css of 31.25 mg/L.
Ingram et al. [82] showed that the risk for development of
acute kidney injury greatly increases when Css exceeds
28 mg/L and 31.5 mg/L is already well above this safety
limit. A target Css less than 28 mg/L is achievable only for
a pathogen with a MIC of maximal 1.8 mg/L. If the MIC of
the pathogen is not known, an empirical target Css of 20–
25 mg/L can be used. Jeurissen showed that to achieve a
target of 25 mg/L a TDD of 3,000 mg with a loading dose
of 1,000 mg should be used in critically ill patients [83]. Be-
cause of the difficulties in predicting correctly both the Vd
and the clearance of vancomycin, it remains advisable to
measure serum levels during the first days of therapy so
that adjustments can be made rapidly.
Vancomycin is stable at room temperature for at least
24 h and can be given in CI. However, the drug is in-
compatible with several other drugs, including most not-
ably β-lactams [64]. Clinicians, therefore, are advised to
infuse vancomycin through a separate line than the one
used for other drugs. Incompatibilities are listed in
Table 5. Because of the risk of red-man syndrome, it also
is advisable to administer the loading dose in no less
than 1–2 h and to use only diluted solutions of vanco-
mycin (typically no more than 10 g/L in 5% glucose).
Drawbacks of continuous infusion
Most notable disadvantages of continuous infusion are
related to the stability of the administered drug, especially
for carbapenems, and incompatibilities with other drugs
as mentioned before. For carbapenems, this limits their
use as “prolonged infusion” (3–4 h), unless solutions are
regularly replaced or special precautions are used, such as
maintaining the solutions at 4°C. For ceftazidime, the in-
stability issues will become important if the surrounding
temperature exceeds 25°C and may necessitate a frequent
replacement (every 8 h) of the solutions. In the ICU, theincompatibility problem is partly overcome through the
frequent use of multiple lumen central venous catheters.
However, on a classic nursing ward where most patients
have standard peripheral venous catheters, this can pose
practical problems. Clinicians should be advised to check
for potential incompatibilities before starting CI (e.g., refer
to the lists in [61,62]) and, in case of difficulty, to resort to
extended dosing regimens (thus alternating the infusion of
the antibiotic with that of the incompatible drug(s).
Another caveat concerns specifically the beta-lactams,
which is the risk of neurological toxicity (encephalopathy,
convulsions). Beta-lactams are known to cause such ad-
verse effects, but most published studies abut CI did not
report its occurrence in patients. Nevertheless, there are
anecdotal reports for neurological adverse effects caused
by cefepime given by CI (especially if its concentrations
exceed 80 mg/L), for reasons that could be related both to
the drug intrinsic toxic potential and the liberation of deg-
radation products (see discussion in [62]). Conversely, no
adverse effect was noted for temocillin, including in
patients with stable levels between 80 and 140 mg/L.
Nevertheless, the clinician should remain aware of this
risk, especially if deciding to aim at a high serum levels,
because of the presence of an organism with a high MIC.
Conclusions
The pursuit for clinical advantages of CI is still open.
There is compelling evidence from PK/PD studies that CI
of beta-lactam antibiotics is superior to II for attainment
of PK/PD targets. Clinical studies have been less convin-
cing and, although they show at least comparable out-
comes between different regimens, they have not been
able until now to show a significant benefit in favor of CI.
However, several studies show important shortcomings,
such as the use of lower antimicrobial dosages in the CI
arm. We conclude that CI of beta-lactam antibiotics is not
necessarily more advantageous for all patients. The benefit
is probably most pronounced in infections with more re-
sistant pathogens and in subpopulations, such as critically
ill or immunocompromised patients. This remains to be
proven in well-designed, clinical studies with simultaneous
in depth PK/PD analysis.
For vancomycin, CI can be chosen, not always for bet-
ter clinical efficacy, but because it is practical, cheaper,
associated with less AUC24h-variability and easier to
monitor. Moreover, it might be associated with a slower
onset of nephrotoxicity. There is, however, still more to
debate about this specific point, and we would strongly
encourage more detailed studies in this context.
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